The ViaNautis fundraise is pivotal, marking a significant step in its journey towards advancing gene therapy and creating value for shareholders.

ViaNautis Bio has secured $25 million in Series A financing to propel the development of its groundbreaking genetic nanomedicines. The company’s proprietary drug delivery platform, polyNaut®, facilitates the transfer of genetic therapeutic payloads across challenging biological barriers, aiming to create new treatments for diseases with unmet clinical needs. Led by 4BIO Capital, BGF, and UCB Ventures, alongside the Cystic Fibrosis Foundation and Eli Lilly and Company, this funding round will accelerate product development, expand teams, and establish cutting-edge laboratory facilities.

PolyNaut® is noted for its use of advanced polymer materials and in silico screening to precisely target genetic molecules like pDNA, mRNA, siRNA, and ASOs. This innovation tackles the hurdle of transporting genetic materials across biological barriers, holding promise for conditions with urgent unmet needs, including Cystic Fibrosis and CNS diseases. ViaNautis’s pipeline includes VNS002, focusing on formulating candidates for targeted delivery to the lungs. (Yahoo Finance)

Established in 2018, ViaNautis emerged from UCL, founded by Dr. Francesca Crawford, Dr. Denis Cecchin, and Professor Giuseppe Battaglia, the inventor of polyNaut®. Francesca Crawford, ViaNautis’s CEO, highlights the potential to address CNS and lung diseases. The fundraise is pivotal, marking a significant step in ViaNautis’s journey towards advancing gene therapy and creating value for shareholders.

Related Story:  Rapport Therapeutics Raises $150 Million For Precision Neuromedicines

Photo by THAVIS 3D on Unsplash